<ul><li>Medical diagnostics company Cytovale has secured $100M in Series D funding round led by Sands Capital.</li><li>The investment will support the expansion of Cytovale's sepsis diagnostic, IntelliSep, to more hospital emergency departments and health systems.</li><li>IntelliSep is the first and only FDA-cleared cellular host diagnostic designed for use in the emergency department for rapid sepsis detection.</li><li>Early adoption of IntelliSep has led to faster treatment, reduced mortality, shorter hospital stays, and cost savings for hospitals.</li></ul>

Cytovale Secures $100M to Expand Commercialization of FDA-Cleared Sepsis Test

Discover more